{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:36:17Z","timestamp":1777350977344,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00109-026-02677-7","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:52:04Z","timestamp":1777348324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pan-cancer ex vivo target evaluation of phosphodiesterase 3\u00a0A (PDE3A)"],"prefix":"10.1007","volume":"104","author":[{"given":"Kiesha","family":"Rice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noora","family":"Lehtinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eetu","family":"V\u00e4lim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"Suhonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Taimen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimmo","family":"Kettunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Ventel\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juha","family":"Kononen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harri","family":"Sihto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4999-5585","authenticated-orcid":false,"given":"Juha K.","family":"Rantala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"8","key":"2677_CR1","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3390\/cells10081998","volume":"10","author":"DM Coenen","year":"2021","unstructured":"Coenen DM, Heinzmann ACA, Oggero S, Albers HJ, Nagy M, Hagu\u00e9 P, Kuijpers MJE, Vanderwinden JM, van der Meer AD, Perretti M, Koenen RR, Cosemans JMEM (2021) Inhibition of phosphodiesterase 3A by cilostazol dampens proinflammatory platelet functions. Cells 10(8):1998","journal-title":"Cells"},{"key":"2677_CR2","doi-asserted-by":"publisher","first-page":"117100","DOI":"10.1016\/j.lfs.2019.117100","volume":"241","author":"AM Taiyeb","year":"2020","unstructured":"Taiyeb AM, Alazzam A, Kjelland ME, Adams TH, Kraemer DC, Muhsen-Alanssari SA, Ridha-Albarzanchi MT (2020) A rapid and efficient method for the collection of highly developmental murine immature oocytes using cilostazol, a phosphodiesterase 3A inhibitor. Life Sci 241:117100","journal-title":"Life Sci"},{"key":"2677_CR3","doi-asserted-by":"publisher","first-page":"647616","DOI":"10.3389\/fcell.2021.647616","volume":"9","author":"PK Roy","year":"2021","unstructured":"Roy PK, Qamar AY, Tanga BM, Fang X, Kim G, Bang S, Cho J (2021) Enhancing oocyte competence with milrinone as a phosphodiesterase 3A inhibitor to improve the development of porcine cloned embryos. Front Cell Dev Biol 9:647616","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"2677_CR4","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1002\/jcb.30328","volume":"123","author":"A Gupta","year":"2022","unstructured":"Gupta A, Trigun SK (2022) Cilostamide, a phosphodiesterase 3A inhibitor, sustains meiotic arrest of rat oocytes by modulating cyclic adenosine monophosphate level and the key regulators of maturation promoting factor. J Cell Biochem 123(12):2030\u20132043","journal-title":"J Cell Biochem"},{"issue":"5","key":"2677_CR5","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1182\/blood-2006-10-052522","volume":"110","author":"W Zhang","year":"2007","unstructured":"Zhang W, Colman RW (2007) Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation\/activation of phosphodiesterase 3A. Blood 110(5):1475\u20131482. https:\/\/doi.org\/10.1182\/blood-2006-10-052522","journal-title":"Blood"},{"issue":"18","key":"2677_CR6","doi-asserted-by":"publisher","first-page":"12339","DOI":"10.1074\/jbc.M807536200","volume":"284","author":"RW Hunter","year":"2009","unstructured":"Hunter RW, Mackintosh C, Hers I (2009) Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets. J Biol Chem 284(18):12339\u201312348. https:\/\/doi.org\/10.1074\/jbc.M807536200","journal-title":"J Biol Chem"},{"issue":"1","key":"2677_CR7","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1038\/s41467-021-24495-w","volume":"12","author":"CW Garvie","year":"2021","unstructured":"Garvie CW, Wu X, Papanastasiou M, Lee S, Fuller J, Schnitzler GR, Horner SW, Baker A, Zhang T, Mullahoo JP, Westlake L, Hoyt SH, Toetzl M, Ranaghan MJ, de Waal L, McGaunn J, Kaplan B, Piccioni F, Yang X, Lange M, Tersteegen A, Raymond D, Lewis TA, Carr SA, Cherniack AD, Lemke CT, Meyerson M, Greulich H (2021) Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. Nat Commun 12(1):4375","journal-title":"Nat Commun"},{"issue":"1","key":"2677_CR8","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-020-17052-4","volume":"11","author":"Y Ai","year":"2020","unstructured":"Ai Y, He H, Chen P, Yan B, Zhang W, Ding Z, Li D, Chen J, Ma Y, Cao Y, Zhu J, Li J, Ou J, Du S, Wang X, Ma J, Gao S, Qi X (2020) An alkaloid initiates phosphodiesterase 3A-schlafen 12 dependent apoptosis without affecting the phosphodiesterase activity. Nat Commun 11(1):3236","journal-title":"Nat Commun"},{"issue":"9","key":"2677_CR9","first-page":"1905","volume":"9","author":"R An","year":"2019","unstructured":"An R, Liu J, He J, Wang F, Zhang Q, Yu Q (2019) PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth. Am J Cancer Res 9(9):1905\u20131921","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2677_CR10","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1038\/s41467-021-26546-8","volume":"12","author":"J Chen","year":"2021","unstructured":"Chen J, Liu N, Huang Y, Wang Y, Sun Y, Wu Q, Li D, Gao S, Wang HW, Huang N, Qi X, Wang X (2021) Structure of PDE3A-SLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells. Nat Commun 12(1):6204. https:\/\/doi.org\/10.1038\/s41467-021-26546-8","journal-title":"Nat Commun"},{"key":"2677_CR11","doi-asserted-by":"publisher","first-page":"816070","DOI":"10.3389\/fonc.2022.816070","volume":"12","author":"F Zhong","year":"2022","unstructured":"Zhong F, Liu J, Gao C, Chen T, Li B (2022) Downstream regulatory network of MYBL2 mediating its oncogenic role in melanoma. Front Oncol 12:816070","journal-title":"Front Oncol"},{"issue":"24","key":"2677_CR12","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1158\/1078-0432.CCR-24-2713","volume":"30","author":"KP Papadopoulos","year":"2024","unstructured":"Papadopoulos KP, McKean M, Goldoni S, Genvresse I, Garrido MF, Li R, Wilkinson G, Kneip C, Yap TA (2024) First-in-human dose-escalation study of the first-in-class PDE3A-SLFN12 complex inducer BAY 2666605 in patients with advanced solid tumors coexpressing SLFN12 and PDE3A. Clin Cancer Res 30(24):5568\u20135576","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2677_CR13","doi-asserted-by":"publisher","first-page":"vdae115","DOI":"10.1093\/noajnl\/vdae115","volume":"6","author":"E Aquilanti","year":"2024","unstructured":"Aquilanti E, Goldoni S, Baker A, Kotynkova K, Andersen S, Bozinov V, Gao GF, Cherniack AD, Lange M, Lesche R, Kopitz C, Lienau P, Lewis TA, Garrido M, Gradl S, Seidel H, Tseng YY, Ligon KL, Wen PY, Meyerson M, Greulich H (2024) Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression. Neurooncol Adv 6(1):vdae115. https:\/\/doi.org\/10.1093\/noajnl\/vdae115","journal-title":"Neurooncol Adv"},{"issue":"2","key":"2677_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.yexcr.2017.10.032","volume":"361","author":"M Nazir","year":"2017","unstructured":"Nazir M, Senkowski W, Nyberg F, Blom K, Edqvist PH, Jarvius M, Andersson C, Gustafsson MG, Nygren P, Larsson R, Frykn\u00e4s M (2017) Targeting tumor cells based on Phosphodiesterase 3A expression. Exp Cell Res 361(2):308\u2013315","journal-title":"Exp Cell Res"},{"issue":"1","key":"2677_CR15","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/s41598-017-02162-9","volume":"7","author":"M Kumazoe","year":"2017","unstructured":"Kumazoe M, Takai M, Hiroi S, Takeuchi C, Yamanouchi M, Nojiri T, Onda H, Bae J, Huang Y, Takamatsu K, Yamashita S, Yamada S, Kangawa K, Takahashi T, Tanaka H, Tachibana H (2017) PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma. Sci Rep 7(1):1917","journal-title":"Sci Rep"},{"issue":"5","key":"2677_CR16","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-18-0815","volume":"25","author":"OP Pulkka","year":"2019","unstructured":"Pulkka OP, Gebreyohannes YK, Wozniak A, Mpindi JP, Tynninen O, Icay K, Cervera A, Keskitalo S, Murum\u00e4gi A, Kulesskiy E, Laaksonen M, Wennerberg K, Varjosalo M, Laakkonen P, Lehtonen R, Hautaniemi S, Kallioniemi O, Sch\u00f6ffski P, Sihto H, Joensuu H (2019) Anagrelide for gastrointestinal stromal tumor. Clin Cancer Res 25(5):1676\u20131687","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2677_CR17","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.3390\/cancers15225308","volume":"15","author":"K Toivanen","year":"2023","unstructured":"Toivanen K, Kilpinen S, Ojala K, Merikoski N, Salmikangas S, Sampo M, B\u00f6hling T, Sihto H (2023) PDE3A Is a highly expressed therapy target in myxoid liposarcoma. Cancers (Basel) 15(22):5308","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2677_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nchembio.1984","volume":"12","author":"L de Waal","year":"2016","unstructured":"de Waal L, Lewis TA, Rees MG, Tsherniak A, Wu X, Choi PS, Gechijian L, Hartigan C, Faloon PW, Hickey MJ, Tolliday N, Carr SA, Clemons PA, Munoz B, Wagner BK, Shamji AF, Koehler AN, Schenone M, Burgin AB, Schreiber SL, Greulich H, Meyerson M (2016) Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol 12(2):102\u2013108","journal-title":"Nat Chem Biol"},{"issue":"3","key":"2677_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41589-022-01170-9","volume":"19","author":"S Lee","year":"2023","unstructured":"Lee S, Hoyt S, Wu X, Garvie C, McGaunn J, Shekhar M, T\u00f6tzl M, Rees MG, Cherniack AD, Meyerson M, Greulich H (2023) Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death. Nat Chem Biol 19(3):301\u2013310","journal-title":"Nat Chem Biol"},{"issue":"10","key":"2677_CR20","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1021\/acsmedchemlett.4c00336","volume":"15","author":"TA Lewis","year":"2024","unstructured":"Lewis TA, Ellermann M, Kopitz C, Lange M, de Waal L, Wu X, Tersteegen A, Denner K, Lienau P, Kaulfuss S, Goldoni S, Meyerson M, Greulich H, Gradl SN (2024) Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12. ACS Med Chem Lett 15(10):1662\u20131667","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"2677_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.neo.2020.06.007","volume":"22","author":"R M\u00e4kel\u00e4","year":"2020","unstructured":"M\u00e4kel\u00e4 R, Arjonen A, Suryo Rahmanto A, H\u00e4rm\u00e4 V, Lehti\u00f6 J, Kuopio T, Helleday T, Sangfelt O, Kononen J, Rantala JK (2020) Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma. Neoplasia 22(9):390\u2013398","journal-title":"Neoplasia"},{"key":"2677_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lungcan.2020.04.036","volume":"145","author":"A Arjonen","year":"2020","unstructured":"Arjonen A, M\u00e4kel\u00e4 R, H\u00e4rm\u00e4 V, Rintanen N, Kuopio T, Kononen J, Rantala JK (2020) Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma. Lung Cancer 145:27\u201332","journal-title":"Lung Cancer"},{"key":"2677_CR23","doi-asserted-by":"publisher","first-page":"735820","DOI":"10.3389\/fonc.2021.735820","volume":"11","author":"N Nyk\u00e4nen","year":"2021","unstructured":"Nyk\u00e4nen N, M\u00e4kel\u00e4 R, Arjonen A, H\u00e4rm\u00e4 V, Lewandowski L, Snowden E, Blaesius R, Jantunen I, Kuopio T, Kononen J, Rantala JK (2021) Ex Vivo Drug screening informed targeted therapy for metastatic parotid squamous cell carcinoma. Front Oncol 11:735820","journal-title":"Front Oncol"},{"key":"2677_CR24","doi-asserted-by":"publisher","first-page":"170166","DOI":"10.1038\/sdata.2017.166","volume":"4","author":"M Hafner","year":"2017","unstructured":"Hafner M, Heiser LM, Williams EH, Niepel M, Wang NJ, Korkola JE, Gray JW, Sorger PK (2017) Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Sci Data 4:170166","journal-title":"Sci Data"},{"key":"2677_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM et al (2025) The present and future of the cancer dependency map. Nat Rev Cancer 25:59\u201373","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2677_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/s-2007-996112","volume":"23","author":"A Tefferi","year":"1997","unstructured":"Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost 23(4):379\u2013383","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2677_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1021\/acsmedchemlett.3c00092","volume":"14","author":"NA Meanwell","year":"2023","unstructured":"Meanwell NA, Anagrelide (2023) A clinically effective cAMP phosphodiesterase 3A inhibitor with molecular glue properties. ACS Med Chem Lett 14(4):350\u2013361","journal-title":"ACS Med Chem Lett"},{"key":"2677_CR28","doi-asserted-by":"publisher","first-page":"101935","DOI":"10.1016\/j.tranon.2024.101935","volume":"44","author":"N Lehtinen","year":"2024","unstructured":"Lehtinen N, Suhonen J, Rice K, V\u00e4lim\u00e4ki E, Toriseva M, Routila J, Halme P, Rahi M, Irjala H, Leivo I, Kallajoki M, Nees M, Kuopio T, Ventel\u00e4 S, Rantala JK (2024) Assessment of targeted therapy opportunities in sinonasal cancers using patient-derived functional tumor models. Transl Oncol 44:101935","journal-title":"Transl Oncol"},{"issue":"11","key":"2677_CR29","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.1074\/jbc.272.11.6823","volume":"272","author":"E Degerman","year":"1997","unstructured":"Degerman E, Belfrage P, Manganiello VC (1997) Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 272(11):6823\u20136826","journal-title":"J Biol Chem"},{"issue":"6220","key":"2677_CR30","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"JO Takanen","year":"2015","unstructured":"Takanen JO, Hober S, Alm T et al (2015) Proteomics. Tissue-based map of the human proteome. Science 347(6220):1260419","journal-title":"Science"},{"issue":"5","key":"2677_CR31","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/ijms22052622","volume":"22","author":"\u00c1 Bartha","year":"2021","unstructured":"Bartha \u00c1, Gy\u0151rffy B (2021) TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci 22(5):2622","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2677_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41416-018-0359-4","volume":"120","author":"BA Brodin","year":"2019","unstructured":"Brodin BA, Wennerberg K, Lidbrink E, Brosj\u00f6 O, Potdar S, Wilson JN, Ma L, Moens LN, Hesla A, Porovic E, Bernhardsson E, Papakonstantinou A, Bauer H, Tsagkozis P, von Sivers K, Wejde J, \u00d6stling P, Kallioniemi O, Stragliotto CL (2019) Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. Br J Cancer 120(4):435\u2013443","journal-title":"Br J Cancer"},{"issue":"16","key":"2677_CR33","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-24-0096","volume":"30","author":"EO Takaki","year":"2024","unstructured":"Takaki EO, Kiyono K, Obuchi Y, Yamauchi T, Watanabe T, Matsumoto H, Karimine M, Kuniyoshi Y, Nishikori S, Yokoyama F, Nishimori H, Nabeshima H, Nakamura K (2024) A PDE3A-SLFN12 Molecular glue exhibits significant antitumor activity in TKI-resistant gastrointestinal stromal tumors. Clin Cancer Res 30(16):3603\u20133621","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2677_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley KA, Yau C, Hinoue T, Cancer Genome JM, Benz CC, Laird PW et al (2018) Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173(2):291\u2013304.e6","journal-title":"Cell"},{"issue":"1","key":"2677_CR35","doi-asserted-by":"publisher","first-page":"2463433","DOI":"10.1080\/10717544.2025.2463433","volume":"32","author":"K Toivanen","year":"2025","unstructured":"Toivanen K, De Sutter L, Wozniak A, Wyns K, Merikoski N, Salmikangas S, Duan J, Maksimow M, Lahtinen M, B\u00f6hling T, Sch\u00f6ffski P, Sihto H (2025) Pharmacokinetic profile and in vivo anticancer efficacy of anagrelide administered subcutaneously in rodents. Drug Deliv 32(1):2463433","journal-title":"Drug Deliv"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02677-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-026-02677-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02677-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:52:05Z","timestamp":1777348325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-026-02677-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2677"],"URL":"https:\/\/doi.org\/10.1007\/s00109-026-02677-7","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient samples were collected between 2016 and 2024 in context of four ongoing clinical studies. The use of patient samples was approved by the Finnish National Supervisory Authority for Welfare and Health (V\/39,706\/2019), regional ethics committee of the University of Turku (51\/1803\/2017, 166\/1801\/2015), University of Turku Hospital (T295\/2023, 64 \/1801\/2022, T0\/021\/18 and T180\/2013-1), Auria biobank scientific board (AB19-6863 and AB18-2741), the regional ethics committee of the wellbeing services county of Southwest Finland (3\/1801\/2013) and the regional ethics committee of the Central Finland Healthcare District, Jyv\u00e4skyl\u00e4 medical center (KSSHP\/3U\/2015). All experiments were undertaken with the understanding and written consent of the patients and the study methodologies conformed to the standards set by the Declaration of Helsinki. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Harri Sihto is a shareholder in Sartar Therapeutics Oy. Juha K. Rantala is the founder of Misvik Biology Oy and an employee of Orion Pharma. Kiesha Rice, Janne Suhonen, and Eetu V\u00e4lim\u00e4ki are employees of Misvik Biology Oy. Noora Lehtinen and Juha Kononen are employees of Docrates Mehil\u00e4inen Oy. The other authors have declared no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}